De Jaeger Katrien, Seppenwoolde Yvette, Boersma Liesbeth J, Muller Sara H, Baas Paul, Belderbos José S A, Lebesque Joos V
Department of Radiotherapy, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1331-40. doi: 10.1016/s0360-3016(02)04389-4.
To study changes of pulmonary function tests (PFTs) after radiotherapy (RT) of non-small-cell lung cancer (NSCLC) in relation to radiation dose, tumor regression, and changes in lung perfusion.
Eighty-two patients with inoperable NSCLC were evaluated with PFTs (forced expiratory volume in 1 s [FEV(1)] and diffusion capacity [T(L,COc)]), a computed tomography (CT) scan of the chest, and a single photon emission CT (SPECT) lung perfusion scan, before and 3-4 months after RT. The reductions of PFTs and tumor volume were calculated. The lung perfusion was measured from pre- and post-RT SPECT scans, and the difference was defined as the measured perfusion reduction (MPR). In addition, the perfusion post-RT was estimated from the dose distribution using a dose-effect relation for regional lung perfusion, and compared with the pre-RT lung perfusion to obtain the predicted perfusion reduction (PPR). The difference between the actually measured and the PPR was defined as reperfusion. The mean lung dose (MLD) was computed and weighted with the pre-RT perfusion, resulting in the mean perfusion-weighted lung dose (MpLD). Changes of PFTs were evaluated in relation to tumor dose, MLD, MpLD, tumor regression, and parameters related to perfusion changes.
In a multivariate analysis, the total tumor dose and MLD were not associated with reductions of PFTs. Tumor regression resulted in a significant improvement of FEV(1) (p = 0.02), but was associated with a reduction of T(L,COc) (p = 0.05). The MpLD and the PPR showed a significant (p = 0.01 to 0.04) but low correlation (r = 0.24 to 0.31) with the reduction of both PFTs. The other parameters for perfusion changes, the MPR and reperfusion were not correlated with changes in PFTs.
The perfusion-related dose variables, the MpLD or the PPR, are the best parameters to estimate PFTs after RT. Tumor regression is associated with an improvement of FEV(1) and a decline of T(L,COc). Reperfusion was not associated with an improvement of global pulmonary function.
研究非小细胞肺癌(NSCLC)放疗(RT)后肺功能测试(PFTs)的变化,及其与辐射剂量、肿瘤退缩和肺灌注变化的关系。
82例无法手术的NSCLC患者在放疗前及放疗后3 - 4个月接受了PFTs(1秒用力呼气量[FEV(1)]和弥散功能[T(L,COc)])、胸部计算机断层扫描(CT)及单光子发射CT(SPECT)肺灌注扫描评估。计算PFTs和肿瘤体积的减少量。通过放疗前后的SPECT扫描测量肺灌注,并将差异定义为测量的灌注减少量(MPR)。此外,利用区域肺灌注的剂量效应关系根据剂量分布估算放疗后的灌注,并与放疗前的肺灌注进行比较,以获得预测的灌注减少量(PPR)。实际测量值与PPR之间的差异定义为再灌注。计算平均肺剂量(MLD),并根据放疗前的灌注进行加权,得出平均灌注加权肺剂量(MpLD)。根据肿瘤剂量、MLD、MpLD、肿瘤退缩以及与灌注变化相关的参数评估PFTs的变化。
在多变量分析中,总肿瘤剂量和MLD与PFTs的降低无关。肿瘤退缩使FEV(1)显著改善(p = 0.02),但与T(L,COc)降低有关(p = 0.05)。MpLD和PPR与两种PFTs的降低均呈显著(p = 0.01至0.04)但低度相关(r = 0.24至0.31)。灌注变化的其他参数,即MPR和再灌注与PFTs的变化无关。
与灌注相关的剂量变量,即MpLD或PPR,是评估放疗后PFTs的最佳参数。肿瘤退缩与FEV(1)改善及T(L,COc)下降有关。再灌注与整体肺功能改善无关。